42 results about "Polyphage" patented technology

Abstract of the Disclosure The present invention relates to methods for selecting repertoires of polypeptides using generic and target ligands. In particular, the invention relates to a library comprising a repertoire of polypeptides of the immunoglobulin superfamily, wherein the members of the repertoire have a known main chain conformation.

The invention relates to an anti-human TIGIT monoclonal antibody which is particularly related to high-affinity anti-human TIGIT monoclonal antibody with blocking activity. A large-capacity fully-synthetic human phage antibody library is constructed, the specific anti-human TIGIT monoclonal antibody and the high-affinity anti-human TIGIT monoclonal antibody which is optimized after molecular evolution are screened from the human phage antibody library, and the monoclonal antibody comprises a full-human frame region and variable regions of a full-human light chain and a heavy chain.

A liver cancer blood vessel specific target polypeptide LCI-X7 able to specific binding with liver cancer blood vessel is extracted from the naked mouse model of human liver cancer by the showing technique of phage random peptide library in body and microscopic laser cutting technique. It provides important theory and practical basis for the diagnosis to liver cancer transfer recurrence and target therapy.

The invention discloses a new cartilaginous affinity polypeptide sequence and a screening method thereof. In the invention, according to an improved phage display technique, a cell and tissue layers combined extracorporeal screening method is applied to cartilaginous affinity polypeptide screening for the first time so as to screen out the polypeptide sequence DWRVIIPPRPSA with chondrocyte affinity and tissue specificity, and thus, the drawback of simple cell screening or tissue screening in the prior art is overcome, and the cellular affinity and the tissue specificity are well combined. The invention also relates to the application of the polypeptide in the preparation of a targeted PEI nano-carrier for the gene therapy of mediated articular cartilage diseases, which realize the decoration on the PEI carrier by the cartilaginous affinity polypeptide, offers the cartilaginous tissue specificity and the cellular affinity to the carrier, and realizes the targeted therapy to the cartilage. In addition, the invention takes the chondrocyte itself as the screening target, which has better targeted effect and clinical practical value compared with the mode of taking the matrixes around the chondrocyte as the screening target in the prior art.

Provided herein are methods, such as phage display assays, for bioengineering peptides that bind to geometrically and / or atomically structured molecular surfaces such as, for example, flat surfaces, smooth curved surfaces, as well as surfaces with periodic, random, or fractal atomic configurations. Surface-binding peptides are provided that are identified using the phage-display methods. Furthermore, scanning probe microscopy (SPM) substrates, biosensors, biochips, and electrodes are provided that include the surface-binding peptides.

This invention belongs to the biomedicine field, involves screening phage peptide library in vitro to get GEBPs. This invention utilizes Transwell co culturing technology to set up culture in vitro models of endothelial cell of stomach cancer blood vessel, through screening phage peptide library in vitro, get GEBPs. The peptides have certain theory meaning and great potential applying value to the research such as stomach cancer diagnosis, blood vessel targeted cure, etc.

The invention relates to a method for screening single chain antibodies of Microcystin-LR and verification thereof. The method comprises the following steps: carrying out two rounds of affinity screening on the biotinylated Microcystin-LR in a human source synthetic antibody library by using an avidin labeled magnetic bead and a negative screening method; extracting total plasmid DNA from phage colonies produced in the second round, carrying out enzyme digestion with enzyme Sfi I, recycling gel to obtain single chain antibody genes, connecting the single chain antibody genes with soluble expression carrier pAK100CL which is processed by enzyme digestion in the same way, and electrically transforming the connected carrier into colibacillus XL1-Blue to obtain soluble expression single chain antibodies; and verifying the soluble expression single chain antibodies by using a competitive time-resolved fluorescence immune analytical method. The invention has the advantage of quick, simple and convenient screening, and can well expose the Microcystin-LR three-dimensional structure into the incubation system. The verification on the screening result has the advantages of high detection signal and strong anti-interference capacity against stroma.

Hydroxyapatite (HA)-binding peptides are selected using combinatorial phage library display. Pseudo-repetitive consensus amino acid sequences possessing periodic hydroxyl side chains in every two or three amino acid sequences are obtained. These sequences resemble the (Gly-Pro-Hyp)x repeat of human type I collagen, a major component of extracellular matrices of natural bone. A consistent presence of basic amino acid residues is also observed. The peptides are synthesized by the solid-phase synthetic method and then used for template-driven HA-mineralization. Microscopy reveal that the peptides template the growth of polycrystalline HA crystals ˜40 nm in size.

The invention is directed to a model system for structure-activity analysis of peptide or protein molecules involved in important biological processes. Provided by the invention are combinatorial peptide libraries comprising disulfide-constrained cyclic peptides with sequences favorable for energy stabilized conformations. One aspect of the invention is directed to cyclic peptide scaffolds that present beta-hairpin structure in solution. Methods of selecting and using such peptide scaffolds are provided herein, which are useful for mimicking in vivo molecular interactions and designing therapeutic agents. Thus, the invention has profound utility for biological studies and drug development.

The invention belongs to the biological technical field, and relates to a targeting nano drug delivery system aiming at brain glioma modified by short peptides of a low density lipoprotein receptor, and a preparation method and application thereof. The drug delivery system comprises target functional molecules, a drug and nano carriers. The target functional molecules are from the short peptides of the low density lipoprotein receptor, obtained by phage display technology. The drug is enveloped in the nano carriers in an enveloping or covalent connection manner, and the short peptides are connected with the polyethylene glycol on the surfaces of the nanoparticles through covalent connection. The drug delivery system can invade and immerse tumor cells by hemato encephalic barrier, can enter into the tumor cells by EPR (enhanced permeability and retention effect), and can promote uptake of brain glioma cells by mediated effect of the low density lipoprotein receptor on the surfaces of the glioma cells so as to improve the effect of anti-brain glioma chemotherapeutics.

The present invention relates to the use of non-pathogenic antibodies to deliver biologically-active proteins to specific cellular and sub-cellular sites. The invention also relates to the use of non-pathogenic antibodies to deliver biologically-active, non-protein molecules to specific cellular and sub-cellular sites.

A method of controlling a deleterious bacteria in a fluid including injecting a nitrite or nitrate into the fluid, identifying a phage capable of infecting the deleterious bacteria, and injecting the phage into the fluid.

The present invention relates to the use of phage display LLG peptide derivatives as tumor targeting agents for diagnostic purposes, and to a method for targeting and imaging tumors and infections / inflammation. A diagnostic composition comprising said peptide derivatives is also disclosed.

Disclosed is a new antibody which can be used to relieve addiction caused by nerve active substances, including opium, cocaine, benzedrine, ketamine, etc. Cocain and amphetamine-regulated transcript peptide antibody gene is selected through phage display technology; then single-chain antibody sequence of the cocain and amphetamine-regulated transcript peptide(CART) and the procaryon expression vector are connected and are induced to express and to be purified to obtain single-chain antibody in response to CART, which is named as CARTscFv(AH1,AH4B,AH6,AH19,AH33B,AH36). Injecteion of CARTscFv into the abdominal cavity of a mouse, together with the CART at the peripheral circulation system, leads to the reduction of the CART in the central nervous system of the mouse. Animal model with behavioral sensitization induced by cocain proves that the CART single-chain antibody can restrain the expression of the behavioral sensitization of the mouse induced by cacain, which shows that the CART single-chain antibody is of great potential in curing addiction and particularly relapse caused by nerve active.

The invention relates to a polypeptide for restraining EGF induced tumor cell proliferation through targeted EGFR and belongs to the technical field of biological medicines. According to the invention, a biological active polypeptide TUZG20 is acquired by taking EGF (Epidermal Growth Factor) as a target molecule, elutriating by adopting a phage display technology, taking EGF as an active ingredient, specifically eluting and combining with the phage of the target molecule. The invention proves that the biological active polypeptide TUZG20 is capable of obviously restraining the gastric carcinoma cell proliferation process caused by EGF. The polypeptide provided by the invention has a short sequence, is easy for compounding and large-scale production, is capable of restraining the tumor-promoting action of EGF, has a potential of subsequently developing into anti-cancer drugs and has an important application value at the aspect of research and development of anti-cancer drugs.

The present invention relates to phages isolates having a strong lytic activity against Enterobacter sakazakii strains and their use as anti-microbial agent in food products, in particular infant formula, and for sanitation of factory environments. The invention also relates to food compositions and anti-microbial agents prepared thereof.

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized in having a specific CS combination and a specific sequence in each CDR. The present scFv library is useful in efficiently producing different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and / or clinical applications.

The invention provides a chemokine receptor 5 antagonist and a pharmaceutical composition. By a phage display technology, screening is carried out to obtain two small molecular active peptides, amino acid sequences of which are respectively GHWKVWL and HYIDFRW. The two polypeptides have a function of antagonizing a chemokine receptor 5 (CCR5) and have high medicinal value. The target molecule is directly located to a molecular structure of CCR5. The studied two heptapeptides are respectively against the first extracellular loop (ECL1) and the second extracellular loop (ECL2) of CCR5. The antagonistic mechanism is definite, and in vitro verification is successful. The invention provides an experimental basis for treatment effect observation of an animal model in the later period.

The invention discloses a preparation method of an RGD-M13 phage / polylysine / oxidized regenerated cellulose composite haemostatic material, and relates to a preparation method of a haemostatic material. The invention aims at solving the problems of an existing oxidized regenerated cellulose modified haemostatic material that a haemostatic time is lightly improved, and the mechanical strength and bio-absorbing property of the oxidized regenerated cellulose are decreased. The method comprises the following steps: I. self-assembly of polylysine; II. self-assembly of an RGD-M13 phage; and III. cleaning and drying, so that the RGD-M13 phage / polylysine / oxidized regenerated cellulose composite haemostatic material is obtained. The RGD-M13 phage / polylysine / oxidized regenerated cellulose composite haemostatic material prepared by the invention, when applied to haemostasis, can shorten the haemostatic time by 25.17%-41.95%. The invention provides the RGD-M13 phage / polylysine / oxidized regenerated cellulose composite haemostatic material.

A method for rapidly preparing an antigen-specific antibody is provided. The method includes establishing an antibody-polypeptide corresponding relationship and an antibody-motif corresponding relationship; finding a polypeptide having a same amino acid sequence with target protein by searching the antibody-polypeptide corresponding relationship, with an antibody corresponding to the polypeptide being the antigen-specific antibody; or calculating the similarity degree between all motifs of each antibody and all modules of the target protein in the antibody-motif corresponding relationship, with an antibody corresponding to a motif the similarity degree of which is greater than 0.4 being the antigen-specific antibody. A phage display technology and a high throughput sequencing technology are combined in the method, information of a polypeptide or motif that can be recognized by the given antibody can be efficiently acquired in an overall manner, the antibody-polypeptide corresponding relationship or the antibody-motif corresponding relationship is established, and through the relationship, the specific antibody corresponding to the target protein can be rapidly determined. The method has a wide application prospect.

The invention provides Amylin compatible polypeptide and an application thereof. The amino acid sequence of the compatible polypeptide is LTPHKHHKHLHA. Firstly the compatible polypeptide sequence of specific binding Amylin is obtained through a phage display library and a biopanning technique, then Amylin and compatible polypeptide are subjected to molecular simulation and constant temperature titer thermal analysis, which indicates that the interaction site of the compatible polypeptide and the Amylin comprises that Amylin aggregation forms hot spot sequence of beta-sheet, and the affinity and the combination specificity of the Amylin and the compatible polypeptide are high. The AFM and ThT fluorescence detection experiment indicates that the compatible polypeptide has obvious restraining effects on the process of forming fibers through Amylin aggregation, and certain theoretical basis and test basis are provided for development of Amylin aggregation inhibitors and drugs relevant with non-insulin dependent diabetes.

This invention relates to biotechnology field of cell and polypeptide. The aim of this invention is screening a small peptide that can strongly combine with MSC, and using it to separate and purify MSC and using it as carrying agent to prepare targeted therapeutic agent. The stated binding peptide sequence of MSC is ringed seven peptide sequence that abundantly contains Ser, Thr, Asn, Lys. Finally this invention uses phage display technique to screen small peptide that can strongly combine with MSC in random libraries of ringed seven peptides by affinity screening with MSC. MSC can link to solid phase sustentaculum through small peptide screened by using this invention. It can be used for screening, separating and purifying MSC. It can be used to prepare tracer agent of MSC after linking with fluorescent tumor marker. It can be used as carrying agent of MSC and medicine to prepare praeparatum about targeted therapy.

Phage display libraries are taught in which the recombinant phage population displays a plurality of potential binding fragments having preferred characteristics of solubility and / or intermolecular interaction. Also taught are methods of biasing display libraries to produce variants which more closely approximate the preferred characteristics of the parental binding fragment.

The present invention relates to the use of non-pathogenic antibodies to deliver biologically-active proteins to specific cellular and sub-cellular sites. The invention also relates to the use of non-pathogenic antibodies to deliver biologically-active, non-protein molecules to specific cellular and sub-cellular sites.

The invention discloses a method for sorting and screening nano antibody through flow cytometry. The method comprises the following steps: (1) collecting peripheral blood B lymphocyte of a camelidae animal with immune target antigen; (2) sorting the B lymphocyte as a single cell by applying target antigen through the flow cytometry; (3) directly performing reverse transcriptional reaction on the sorted single B lymphocyte to generate cDNA; (4) taking the cDNA as a template, performing PCR amplification on an antibody heavy chain sequence and recycling an amplified product; (5) taking the amplified product in the step (4) as a template, and performing PCR amplification on CH1 and CH2 sequence coding genes of the antibody; (6) taking the amplified product in the step (4) which is amplified to be negative in the step (5) as a template, and performing PCR amplification on a VHH segment coding gene of the antibody; (7) cloning a VHH segment obtained in the step (6) into an expression vector, and expressing the VHH segment in host bacteria; and (8) identifying the nano antibody which is pressed in the step (7). The method disclosed by the invention is simple to operate, is short in screening period, avoids phage pollution risk, improves screening efficiency, reduces workload greatly, is low in economic cost, and is suitable for industrial large-batch screening requirements.

The invention belongs to the technical field of biological medicines, and discloses an MSTN nano antibody, a construction method and application thereof. Constructing a nano antibody library of sheepMSTN gene expression product; obtaining a specific nano antibody aiming at an MSTN gene expression product through a phage display technology; and constructing a bivalent sheep MSTN nano antibody; theMSTN nano antibody has the functions of increasing animal muscle content and reducing animal fat content on mice. When the weight gain was mainly muscle weight gain, the sheep MSTN nano antibody showed that the weight gain was higher than that of untreated control group; mice showed that the muscle weight of the nano antibody group was significantly higher than that of the control group, and thepercentage of muscle in the whole body was also significantly higher than that of the control group. Sheep MSTN nano antibodies can promote muscle growth in animals.

A novel family of protein libraries comprising CTLDs (C-type Lectin-Like Domains) in which internal polypeptide loop-regions lining the ligand binding sites in CTLDs have been replaced with ensembles of completely or partially randomised polypeptide segments. Tetranectin CTLDs were chosen as framework for the preferred embodiment of the invention; and versatile phagemid vectors useful in the generation and manipulation of human and murine tetranectin CTLD libraries are disclosed as part of this invention. Tetranectin CTLDs in monomeric as well as in trimeric form are efficiently displayed as gene III fusions in fully functional form by the recombinant fd phage display vector. CTLD derivatives with affinity for new ligands may readily be isolated from libraries of vectors displaying CTLDs, in which loop-regions have been randomised, using one or more rounds of enrichment by screening or selection followed by amplification of the enriched subpopulation in each round. The efficiency with which protein products containing CTLDs with new binding properties can be produced, e.g. by bacterial expression and in vitro refolding, in mono-, tri-, or multimeric formats provides important advantages in terms of simplicity, cost and efficiency of generation, production and diagnostic or therapeutic applications in comparison to recombinant antibody derivatives.

The invention relates to a specific polypeptide targeted binding to lymphoma cell lines and application thereof, and belongs to the field of biomedicine. The specific polypeptide is based on a phage display technology in vitro, in vitro panning and obtaining a specific polypeptide TUZG12 capable of targeted binding the lymphoma cell lines. In vitro cell uptake and distribution experiments prove that the polypeptide has targeted binding activities to the lymphoma cell lines. According to the specific polypeptide targeted binding to the lymphoma cell lines, the results of in vitro cell viabilityexperiments show that the pro-apoptotic peptide DKK can enhance the inhibitory effect of DKK on proliferation of lymphoma cells to a certain extent after coupling TUZG12 polypeptide. The polypeptidescreened in the invention has good targeted binding activities to multiple lymphoma cell lines, and can enhance the killing effect of cytotoxic polypeptides on target tumor cells, and has an importantapplication value in the clinical diagnosis and treatment of lymphoma.